SIRT5 Blocks Cardiac Fibrosis by Rewiring Fibroblast Metabolism
A sirtuin enzyme prevents heart scarring by keeping cardiac fibroblasts from switching to a pro-fibrotic metabolic state.
Summary
Cardiac fibrosis — the scarring of heart tissue — drives heart failure, yet few targeted therapies exist. Researchers discovered that SIRT5, a mitochondrial sirtuin enzyme, is sharply reduced in cardiac fibroblasts from failing human and mouse hearts. When SIRT5 is lost, fibroblasts shift from efficient mitochondrial energy production to glycolysis, a metabolic switch that activates them into scar-forming cells. The mechanism involves a chemical modification called succinylation on a metabolic enzyme called PCK2 at a specific site (Lys489). SIRT5 normally removes this modification, keeping PCK2 active and metabolism balanced. Restoring SIRT5 or blocking PCK2 succinylation in mice significantly reduced heart scarring and preserved cardiac function. These findings identify SIRT5 and the PCK2 succinylation pathway as promising therapeutic targets for cardiac fibrosis.
Detailed Summary
Cardiac fibrosis — the progressive replacement of healthy heart muscle with stiff scar tissue — is a central driver of heart failure, affecting millions worldwide. Despite its clinical importance, disease-modifying treatments that directly target fibrosis remain limited. This study investigates a previously underexplored role for SIRT5, a mitochondrial member of the sirtuin deacylase family, in regulating the fibroblasts responsible for that scarring.
Researchers from Sun Yat-sen University analyzed cardiac fibroblasts (CFBs) from human and mouse hearts with heart failure, finding that SIRT5 expression was markedly reduced and inversely correlated with fibrosis severity. Using cardiac fibroblast-specific knockout and overexpression mouse models, they confirmed that SIRT5 loss worsened left ventricular dysfunction, cardiac hypertrophy, and fibrosis after pressure overload, while SIRT5 overexpression was protective.
The mechanistic core of the study centers on PCK2, an enzyme that bridges glycolysis and the tricarboxylic acid (TCA) cycle. Without SIRT5, PCK2 accumulates a succinyl group at lysine residue 489 (Lys489), inhibiting its activity. This drives fibroblasts to abandon oxidative phosphorylation in favor of glycolysis — a metabolic reprogramming that activates them into pro-fibrotic, collagen-depositing cells. Introducing a Lys489-to-arginine mutation that prevents succinylation fully reversed both the metabolic shift and fibroblast hyperactivation, even in SIRT5-deficient animals.
These findings establish a clear molecular axis: SIRT5 → PCK2 desuccinylation → metabolic homeostasis → suppressed fibroblast activation → reduced cardiac fibrosis. The pathway is conserved across human and mouse tissue, strengthening translational relevance.
Clinically, this work suggests that activating SIRT5 or pharmacologically targeting PCK2 succinylation could represent novel strategies to treat or prevent cardiac fibrosis in heart failure patients. Caveats include reliance on abstract-level data, predominantly preclinical mouse models, and the need for pharmacological tools to validate the pathway in humans.
Key Findings
- SIRT5 expression is significantly reduced in cardiac fibroblasts from failing human and mouse hearts.
- SIRT5 loss drives fibroblasts from oxidative phosphorylation to glycolysis, activating pro-fibrotic behavior.
- SIRT5 desuccinylates PCK2 at Lys489, keeping this metabolic enzyme active and fibroblasts quiescent.
- Blocking PCK2 succinylation (K489R mutation) fully rescued cardiac fibrosis in SIRT5-deficient mice.
- Overexpressing SIRT5 in cardiac fibroblasts significantly reduced heart scarring and preserved function.
Methodology
The study used cardiac fibroblast-specific Sirt5 knockout and overexpression mouse models subjected to transverse aortic constriction (pressure overload). Mechanistic validation employed a Pck2 K489R knock-in mutation to block succinylation in both cell culture and in vivo models. Human heart failure tissue was analyzed to confirm translational relevance of SIRT5 expression changes.
Study Limitations
This summary is based on the abstract only, as the full text is not open access, limiting assessment of statistical rigor and experimental detail. The study is predominantly preclinical, relying on mouse models; human validation is limited to expression correlation data. Pharmacological tools to modulate SIRT5 or PCK2 succinylation in humans have not yet been developed or tested.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.